merged_eli-lilly-zepbound-price.txt


<question_number>1</question_number>
<answer>safety concerns due to less oversight of compounded drugs</answer>

<question_number>2</question_number>
<answer>direct delivery through LillyDirect telehealth platform</answer>

<question_number>3</question_number>
<answer>lack of FDA oversight on safety, quality, effectiveness</answer>

<question_number>4</question_number>
<answer>recapturing customers from compounders despite self-cannibalization</answer>

<question_number>5</question_number>
<answer>compounders can legally produce only if drug is on FDA shortage list</answer>

<question_number>6</question_number>
<answer>removing third-party supply chain entities for transparent pricing</answer>

<question_number>7</question_number>
<answer>increased use by Medicare patients despite muscle loss risks</answer>

<question_number>8</question_number>
<answer>positioning vials as safer FDA-approved alternative</answer>

<question_number>9</question_number>
<answer>FDA listing tirzepatide as "in shortage"</answer>

<question_number>10</question_number>
<answer>signaling market share reclamation via lower pricing</answer>